Company Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds.
Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Apr 8, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Jasbir Seehra |
Contact Details
Address: 1050 Waltham Street, Suite 302 Lexington, Massachusetts 02421 United States | |
| Phone | 617 314 6297 |
| Website | kerostx.com |
Stock Details
| Ticker Symbol | KROS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1664710 |
| CUSIP Number | 492327101 |
| ISIN Number | US4923271013 |
| Employer ID | 81-1173868 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jasbir S. Seehra Ph.D. | President, Chief Executive Officer and Director |
| Keith C. Regnante MBA | Chief Financial Officer |
| Esther Cho J.D. | Chief Legal Officer and Secretary |
| Dr. Lorena Lerner Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 9, 2026 | 8-K | Current Report |
| Mar 4, 2026 | 8-K | Current Report |
| Mar 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2026 | 10-K | Annual Report |
| Mar 4, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |